Increasing importance of stem cell gene therapy in adenosine deaminase deficiency? [1]

Clinical and Vaccine Immunology

Volumn 13, Issue 3, 2006, Pages 433-434

  Özdemir, Öner ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; PEGADEMASE;

ADENOSINE DEAMINASE DEFICIENCY; AUTOIMMUNE DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; HUMAN; IMMUNE DYSREGULATION; LETTER; PRIORITY JOURNAL; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; TH2 CELL; THROMBOCYTOSIS; THYMUS DISEASE;

ADENOSINE DEAMINASE; ANIMALS; GENE THERAPY; HUMANS; MICE; STEM CELL TRANSPLANTATION;

EID: 33645541888     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.3.433-435.2006     Document Type: Letter

References (17)

1. Aiuti, A. 2004. Gene therapy for adenosine-deaminase-deficient severe combined immunodeficiency. Best Pract. Res. Clin. Haematol. 17:505-516.
2. Aiuti, A., S. Slavin, M. Aker, F. Ficara, S. Deola, A. Mortellaro, S. Morecki, G. Andolfi, A. Tabucchi, F. Carlucci, E. Marinello, F. Cattaneo, S. Vai, P. Servida, R. Miniero, M. G. Roncarolo, and C. Bordignon. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-2413.
3. Blackburn, M. R., M. Aldrich, J. B. Volmer, W. Chen, H. Zhong, S. Kelly, M. S. Hershfield, S. K. Datta, and R. E. Kellems. 2000. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. J. Biol. Chem. 275:32114-32121.
4. Buckley, R. H., S. E. Schiff, R. I. Schiff, L. Markert, L. W. Williams, J. L. Roherts, L. A. Myers, and F. E. Ward. 1999. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340:508-516.
5. Cavazzana-Calvo, M., and A. Fischer. 2004. Efficacy of gene therapy for SCID is being confirmed. Lancet 364:2155-2156.
6. Chan, B., D. Wara, J. Bastian, M. S. Hershfield, J. Bohnsack, C. G. Azen, R. Parkman, K. Weinberg, and D. B. Kohn. 2005. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 117:133-143.
7. Chinen, J., and J. M. Puck. 2004. Perspectives of gene therapy for primary immunodeficiencies. Curr. Opin. Allergy Clin. Immunol. 4:523-527.
8. Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
9. Hershfield, M. S., S. Chaffee, and R. U. Sorensen. 1993. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Pediatr. Res. 33:S42-S48.A.
10. Hirschhorn, R. 1999. Immunodeficiency disease due to deficiency of adenosine deaminase, p. 121-139. In H. D. Ochs, C. I. E. Smith, and J. M. Puck (ed.), Primary immunodeficiency diseases. A molecular and genetic approach. Oxford University Press, Oxford, United Kingdom.
11. Kaufman, D. A., M. S. Hershfield, J. A. Bocchini, I. J. Moissidis, M. Jeroudi, and S. L. Bahna. 1 November 2005. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. Pediatrics 116: c879-c879. [Epub ahead of print.]
12. Lainka, E., M. S. Hershfield, I. Santisteban, P. Bali, A. Seibt, J. Neuhert, W. Friedrich, and T. Niehues. 2005. Polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency. Clin. Diagn. Lab. Immunol. 12:861-866.
13. Lee, J. Y., J. Hempel, and J. S. Deng. 2002. Anti-adenosine deaminase antibodies in lupus erythematosus. Lupus 11:168-174.
14. Malacarne, F., T. Benicchi, L. D. Notarangelo, L. Mori, S. Parolini, L. Caimi, M. Hershfield, L. D. Notarangelo, and L. Imberti. 2005. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur. J. Immunol. 35:3376-3386.
15. Marwaha, V. R., D. H. Italia, F. Esper, and R. W. Hostoffer. 2000. Extreme thrombocytosis inresponse to PEG-ADA: early therapeutic and risk indicator. Clin. Pediatr. (Philadelphia) 39:183-186.
16. Notarangelo, L. D., G. Stoppoloni, R. Toraldo, E. Mazzolari, A. Coletta, P. Airo, C. Bordignon, and A. G. Ugazio. 1992. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur. J. Pediatr. 151:811-814.
17. Sakiyama, Y., T. Ariga, and M. Ohtsu. 2005. Gene therapy for adenosine deaminase deficiency. Nippon Rinsho 63:448-452.